Related News »
Merck did so when generic competition hit for two prior bestsellers, osteoporosis drug Fosamax in February 2008 and cholesterol pill Zocor in June 2006 ... Frazier, who is Merck's president and chairman, received total compensation of about ...
May 22, 2012 at 15:10 | Source: CBS News
OVERVIEW: Zocor (simvastatin) is a synthetic statin developed by Merck & Co., which is now widely available as generic simvastatin. Before patent protections expired in 2005, it was Merck’s best-selling drug and the second best selling cholesterol ...
May 25, 2012 at 13:26 | Source: AboutLawsuits.com
The pharmaceutical giants all have their own version of cholesterol-lowering statin: Merck’s Zocor, AstraZeneca’s Crestor, and Pfizer’s Lipitor, which has become the most profitable drug of all time at sales of over $130 billion.
May 19, 2012 at 23:56 | Source: Singularity Hub (blog)
Merck's products include Zocor for treatment of elevated cholesterol, Propecia for treatment for male pattern hair loss, Fosamax for preventive treatment of osteoporosis, and Singulair for treatment of asthma. Merck was founded in 1891 and is headquartered ...
May 14, 2012 at 09:07 | Source: TradersHuddle.com
Lipitor is not the first statin to go off patent. Merck's (MRK) Zocor has been available as a generic since 2006, which has pressured the sales of other more expensive statins like Lipitor and Crestor (marketed by AstraZeneca (AZN). Pfizer has a well ...
May 11, 2012 at 15:44 | Source: Seekingalpha.com
Merck did so when generic competition hit for two prior bestsellers, osteoporosis drug Fosamax in February 2008 and cholesterol pill Zocor in June 2006 ... Frazier, who is Merck's president and chairman, received total compensation of about ...
May 26, 2012 at 19:30 | Source: Yahoo Finance
Merck's anacetrapib is in a huge late-stage study ... include Lipitor and Crestor, plus the older drugs Zocor, Mevacor and Pravachol. Testing of CETP inhibitors has been among the most expensive drug development programs even though not everyone ...
May 7, 2012 at 19:52 | Source: Marin Independent Journal
The promise of a drug that could be an heir to best-selling LDL lowering medicines such as Lipitor and Zocor is just too big to pass ... CETP inhibitors that are much more potent. Merck’s drug, anacetrapib, increased HDL by 138% in one study ...
May 7, 2012 at 12:29 | Source: Forbes